pulmonari
infect
common
complic
lung
transplant
earli
detect
crucial
outcom
howev
condit
clinic
difficult
diagnos
distinguish
reject
aim
prospect
studi
evalu
heparinbind
protein
hbp
lysozym
cytokin
interleukin
il
tumor
necrosi
factor
tnf
bronchoalveolar
lavag
fluid
balf
potenti
biomark
pulmonari
infect
lungtranspl
patient
one
hundr
thirteen
balf
sampl
lung
transplant
recipi
collect
routin
schedul
bronchoscopi
month
clinic
indic
sampl
classifi
possibl
probabl
definit
infect
time
sampl
reject
defin
biopsi
result
hbp
lysozym
cytokin
analyz
balf
correl
likelihood
infect
reject
biomark
significantli
increas
balf
infect
wherea
patient
reject
present
low
level
compar
noninfect
sampl
hbp
best
diagnost
marker
infect
area
receiveroper
characterist
curv
valu
respect
conclus
hbp
could
use
diagnost
marker
pulmonari
infect
lungtranspl
patient
k
e
w
r
basic
laboratori
researchsci
bronchoalveolar
lavag
bal
clinic
researchpractic
cytokinescytokin
receptor
infecti
diseas
lung
diseas
infecti
lung
transplant
pulmonolog
reject
therefor
difficult
distinguish
clinic
howev
lntx
patient
may
lack
classic
sign
infect
due
heavi
immunosuppress
reject
may
asymptomat
addit
possibl
link
infect
develop
reject
exampl
viral
pneumonia
associ
chronic
lung
allograft
dysfunct
graft
loss
antimicrobi
peptid
respiratori
secret
play
import
role
first
line
defenc
infect
lysozym
abund
airway
antimicrobi
peptid
secret
primarili
neutrophil
submucos
gland
heparinbind
protein
hbp
initi
recogn
broad
antimicrobi
activ
known
multifunct
inflammatori
mediat
induc
vascular
leakag
act
chemoattract
activ
monocyt
protein
store
secretori
azurophil
granul
neutrophil
rapidli
releas
upon
cell
activ
plasma
hbp
describ
promis
biomark
sever
sepsi
septic
shock
elev
hbp
level
also
shown
cerebrospin
fluid
bacteri
mening
urin
urinari
tract
infect
neither
hbp
lysozym
previous
evalu
balf
lntx
patient
studi
quantifi
two
protein
togeth
proinflammatori
cytokin
interleukin
il
tnf
antiinflammatori
balf
collect
first
year
transplant
primari
aim
evalu
hbp
lysozym
potenti
biomark
infect
determin
abil
discrimin
infect
reject
lung
transplant
recipi
prospect
cohort
studi
conduct
univers
hospit
one
two
center
sweden
perform
lntx
adult
patient
accept
lntx
studi
period
octob
decemb
elig
inclus
patient
younger
year
age
patient
postop
followup
site
exclud
studi
particip
follow
maximum
year
transplant
written
inform
consent
obtain
studi
patient
studi
approv
region
ethic
committe
reg
nr
perform
accord
ethic
standard
declar
helsinki
later
amend
standard
protocol
immun
suppress
includ
induct
therapi
atg
antithymocyt
globulin
follow
tacrolimu
cyclosporin
mycophenol
mofetil
steroid
lntx
recipi
treat
cytomegaloviru
fungal
prophylaxi
month
balf
sampl
collect
routin
schedul
bronchoscopi
month
lntx
diagnost
bronchoscopi
perform
respons
clinic
symptom
minim
interv
day
allow
bal
includ
new
sampl
studi
bal
procedur
follow
standard
protocol
studi
sampl
analys
hbp
lysozym
cytokin
obtain
instal
ml
phosphatebuff
salin
pb
initi
ml
balf
discharg
studi
sampl
ml
collect
portion
ml
pb
instil
collect
balf
accord
standard
protocol
bacteri
fungal
cytolog
analys
balf
sent
univers
tbb
semiquantit
report
mild
acuteabund
inflamm
likelihood
pulmonari
infect
time
balf
sampl
independ
blind
result
biomark
adjust
dilut
balf
estim
biomark
concen
chisquar
rank
sum
kruskalw
mannwhitney
u
test
use
logist
regress
calcul
odd
ratio
or
infect
dichotom
definit
probabl
vs
possibl
infect
reject
biomark
use
gener
estim
equat
gee
model
account
possibl
depend
due
multipl
observ
patient
differ
biomark
first
analyz
univari
model
secondli
model
adjust
time
lntx
statist
test
twosid
confid
interv
ci
total
patient
transplant
studi
period
five
patient
elig
inclus
due
followup
anoth
center
one
patient
declin
particip
consequ
patient
includ
studi
four
particip
die
shortli
transplant
studi
sampl
collect
leav
lung
transplant
recipi
prospect
follow
studi
patient
women
men
median
age
year
underw
doubl
lung
transplant
cystic
fibrosi
common
underli
diseas
detail
patient
characterist
see
tabl
patient
assess
infect
time
bal
describ
tabl
bacteri
growth
detect
balf
sampl
pseudomona
aeruginosa
commonli
isol
bacteri
speci
follow
escherichia
coli
hbp
cutoff
valu
ngml
sensit
specif
detect
infect
posit
predict
valu
ppv
neg
predict
valu
npv
respect
perform
similar
hbp
wherea
lysozym
show
poor
sensit
specif
tabl
prospect
studi
lung
transplant
recipi
compar
differ
biomark
predict
infect
found
hbp
similar
hbp
lysozym
cytokin
increas
likelihood
infect
mirror
increas
inflamm
antiinflammatori
properti
show
pattern
proinflammatori
cytokin
studi
believ
play
import
role
balanc
inflammatori
respons
order
limit
host
tissu
damag
exampl
compar
wildtyp
mice
mice
demonstr
effici
bacteri
clearanc
higher
mortal
increas
neutrophil
recruit
lung
respons
streptococcu
pneumonia
infect
underscor
regulatori
role
infect
could
therefor
specul
increas
simultan
proinflammatori
cytokin
order
avoid
excess
inflamm
would
harm
host
correct
dilut
factor
balf
use
urea
method
studi
found
signific
differ
level
reject
noninfect
biomark
contrari
result
patella
et
al
demonstr
increas
level
reject
compar
reject
one
possibl
reason
discrep
reject
defin
differ
two
studi
identifi
reject
tbb
ensur
correct
diagnosi
test
biomark
common
indic
neutrophildomin
inflamm
contrast
reject
primarili
celldriven
process
